Trials / Completed
CompletedNCT04721106
Korea Post Marketing Surveillance (PMS) Study of Vizimpro
A Prospective, Single-arm, Open-label, Non-interventional, Multi-centre, Post Marketing Surveillance (PMS) Study of Vizimpro®
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 188 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Vizimpro will be approved for the treatment of EGFR NSLCL 1L in Korea. In accordance with the Standards for Re-examination of New Drug, it is required to conduct a PMS. Post marketing surveillance is required to determine any problems or questions associated with Vizimpro after marketing in Korea, with regard to the following clauses under conditions of general clinical practice. Therefore, through this study, effectiveness and safety of Vizimpro will be observed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vizimpro | treatment group |
Timeline
- Start date
- 2021-03-07
- Primary completion
- 2026-01-19
- Completion
- 2026-01-19
- First posted
- 2021-01-22
- Last updated
- 2026-02-10
Locations
1 site across 1 country: South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04721106. Inclusion in this directory is not an endorsement.